Cargando…

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia

The importance of medication adherence in sustaining control of schizophrenic symptoms has generated a great deal of interest in comparing levels of treatment adherence with different antipsychotic agents. However, the bulk of the research has yielded results that are often inconsistent. In this pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Xinhua S, Herz, Lawrence, Qian, Shirley, Smith, Eric, Kazis, Lewis E
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762365/
https://www.ncbi.nlm.nih.gov/pubmed/19851516
_version_ 1782172915554320384
author Ren, Xinhua S
Herz, Lawrence
Qian, Shirley
Smith, Eric
Kazis, Lewis E
author_facet Ren, Xinhua S
Herz, Lawrence
Qian, Shirley
Smith, Eric
Kazis, Lewis E
author_sort Ren, Xinhua S
collection PubMed
description The importance of medication adherence in sustaining control of schizophrenic symptoms has generated a great deal of interest in comparing levels of treatment adherence with different antipsychotic agents. However, the bulk of the research has yielded results that are often inconsistent. In this prospective, observational study, we assessed the measurement properties of 3 commonly used, pharmacy-based measures of treatment adherence with antipsychotic agents in schizophrenia using data from the Veterans Health Administration during 2000 to 2005. Patients were selected if they were on antipsychotics and diagnosed with schizophrenia (N = 18,425). A gap of ≥30 days (with no filled index medication) was used to define discontinuation of treatment as well as medication “episodes,” or the number of times a patient returned to the same index agent after discontinuation of treatment within a 1-year period. The study found that the 3 existing measures differed in their approaches in measuring treatment adherence, suggesting that studies using these different measures would generate different levels of treatment adherence across antipsychotic agents. Considering the measurement problems associated with each existing approach, we offered a new, medication episode-specific approach, which would provide a fairer comparison of the levels of treatment adherence across different antipsychotic agents.
format Text
id pubmed-2762365
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27623652009-10-22 Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia Ren, Xinhua S Herz, Lawrence Qian, Shirley Smith, Eric Kazis, Lewis E Neuropsychiatr Dis Treat Original Research The importance of medication adherence in sustaining control of schizophrenic symptoms has generated a great deal of interest in comparing levels of treatment adherence with different antipsychotic agents. However, the bulk of the research has yielded results that are often inconsistent. In this prospective, observational study, we assessed the measurement properties of 3 commonly used, pharmacy-based measures of treatment adherence with antipsychotic agents in schizophrenia using data from the Veterans Health Administration during 2000 to 2005. Patients were selected if they were on antipsychotics and diagnosed with schizophrenia (N = 18,425). A gap of ≥30 days (with no filled index medication) was used to define discontinuation of treatment as well as medication “episodes,” or the number of times a patient returned to the same index agent after discontinuation of treatment within a 1-year period. The study found that the 3 existing measures differed in their approaches in measuring treatment adherence, suggesting that studies using these different measures would generate different levels of treatment adherence across antipsychotic agents. Considering the measurement problems associated with each existing approach, we offered a new, medication episode-specific approach, which would provide a fairer comparison of the levels of treatment adherence across different antipsychotic agents. Dove Medical Press 2009 2009-10-12 /pmc/articles/PMC2762365/ /pubmed/19851516 Text en © 2009 Ren et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Ren, Xinhua S
Herz, Lawrence
Qian, Shirley
Smith, Eric
Kazis, Lewis E
Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
title Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
title_full Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
title_fullStr Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
title_full_unstemmed Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
title_short Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
title_sort measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762365/
https://www.ncbi.nlm.nih.gov/pubmed/19851516
work_keys_str_mv AT renxinhuas measurementoftreatmentadherencewithantipsychoticagentsinpatientswithschizophrenia
AT herzlawrence measurementoftreatmentadherencewithantipsychoticagentsinpatientswithschizophrenia
AT qianshirley measurementoftreatmentadherencewithantipsychoticagentsinpatientswithschizophrenia
AT smitheric measurementoftreatmentadherencewithantipsychoticagentsinpatientswithschizophrenia
AT kazislewise measurementoftreatmentadherencewithantipsychoticagentsinpatientswithschizophrenia